High-Dose Vitamin C IV

High-dose intravenous vitamin C has been investigated across several clinical areas, with the most robust evidence in critical care settings, particularly sepsis, and emerging research in oncology applications.

Sepsis and Critical Illness

The strongest clinical evidence supports the use of high-dose IV vitamin C in critically ill patients with sepsis. The Phase 2b ASTER trial specifically evaluated ascorbate for organ dysfunction in sepsis patients, representing one of the most rigorous studies in this area. Additional retrospective analysis from the MIMIC-IV database found that vitamin C was associated with improved outcomes in patients with sepsis-induced myocardial injury, suggesting potential cardioprotective benefits in this population.

Oncology Applications

Several clinical trials have explored high-dose IV vitamin C as an adjunct to cancer treatment:

• A completed Phase 1 study (NCT00441207) examined high-dose IV vitamin C treatment in patients with solid tumors
• A Phase 1/2 trial (NCT03410030) combined ascorbic acid with nanoparticle paclitaxel, cisplatin, and gemcitabine, which has been completed
• Laboratory research suggests that high-dose vitamin C may promote mitochondrial biogenesis in colorectal cancer cells and potentially work synergistically with oncolytic adenoviruses to induce tumor ferroptosis

However, it should be noted that one pancreatic cancer trial (NCT03908333) combining high-dose ascorbic acid with chemotherapy was withdrawn, indicating ongoing challenges in this application area.

Pain and Neurological Conditions

A recent case report documented successful treatment of neuropathic symptoms in acute trigeminal herpes zoster using high-dose intravenous ascorbic acid in two patients. While promising, this represents very limited evidence requiring further validation in controlled studies.

Burn Treatment

Research has compared low-dose versus high-dose vitamin C protocols in burn patients with >20% total body surface area burns, though specific outcomes from this completed study are not detailed in the available evidence.

Safety Considerations

A systematic review has evaluated both the clinical benefits and risks of high-dose intravenous vitamin C, though specific findings are not detailed in the available abstracts. One notable safety consideration identified in veterinary research showed that high-dose IV vitamin C can cause false elevations in glucose monitor readings, which could have clinical monitoring implications.

The evidence base for high-dose IV vitamin C remains mixed, with the strongest support in sepsis management and ongoing investigation in oncology. Many applications require further controlled clinical trials to establish definitive efficacy and safety profiles.

This information is for educational purposes only and should not replace professional medical advice. Patients should consult with their healthcare providers before considering any treatment.